2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.
Lori A. Leslie, MD, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, discusses the methods utilized in the phase 3 ZUMA‑7 trial (NCT03391466) in relapsed/refractory large B-cell lymphoma (LBCL).
The study randomized patients 1:1 to receive either the CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta), or platinum-based salvage chemotherapy followed by autologous stem cell transplantation (ASCT), Leslie says.
Notably, 94% of patients randomized to the CAR-T arm were administered axi-cel, compared with 36% of patients in the standard-of-care arm who received an ASCT, Leslie explains. High-risk patients tend to become chemorefractory, underscoring the need to get more patients to ASCT under the current standard of care, Leslie concludes.